-transparent.png){kind=logo}
Doxorubicin and five synthesized metabolites (doxorubicinol, doxorubicin aglycone, doxorubicinol aglycone, 7-deoxydoxorubicin aglycone, and 7-deoxydoxorubicinol aglycone) were evaluated in vitro for their cytotoxic effect on human marrow erythroid burst- and granulocytic-monocytic colony-forming units (BFU-E, CFU-GM). The IC50 for doxorubicin was 0.39 +/- 0.099 micron and for doxorubicinol was 4.6 +/- 0.63 micron. There was no difference in cytotoxicity for BFU-E or CFU-GM. Incubation with aglycones in concentrations as high as 5.8 micron and prolongation of incubation time for as long as 3 hours had no effect on the growth of BFU-E and CFU-GM in vitro. We conclude that aglycones are not toxic to human marrow erythroid and myeloid progenitors in vitro and do not have a role in the development of doxorubicin-induced myelotoxicity. The mechanism of the lack of cytotoxicity remains unclear.
E N Dessypris, and
D E Brenner, and
K R Hande
July 1997,
Journal of lipid mediators and cell signalling,
E N Dessypris, and
D E Brenner, and
K R Hande
July 1992,
Chinese medical journal,
E N Dessypris, and
D E Brenner, and
K R Hande
February 1994,
Journal of the National Cancer Institute,
E N Dessypris, and
D E Brenner, and
K R Hande
March 1994,
Leukemia,
E N Dessypris, and
D E Brenner, and
K R Hande
January 1985,
Progress in clinical and biological research,
E N Dessypris, and
D E Brenner, and
K R Hande
June 2016,
European cytokine network,
E N Dessypris, and
D E Brenner, and
K R Hande
December 2001,
Haematologica,
E N Dessypris, and
D E Brenner, and
K R Hande
June 1987,
Blood,
E N Dessypris, and
D E Brenner, and
K R Hande
July 1990,
Pathology,
E N Dessypris, and
D E Brenner, and
K R Hande
March 2015,
Blood,
